Characteristics | No. of patients (%) | Median OS (months) | P value |
---|---|---|---|
Sex | |||
Male | 64 (87.0) | 9.3 | 0.860 |
Female | 18 (22.0) | 10.3 | |
Age (y) | |||
Median | 59 | ||
Range | 39–73 | ||
< 65 | 44 (53.7) | 12.3 | 0.349 |
≥ 65 | 38 (46.3) | 9.2 | |
KPS | |||
≥ 70 | 76 (92.7) | 11.2 | 0.032* |
> 70 | 6 (7.3) | 5.0 | |
Smoking history | |||
Yes | 64 (78.0) | 9.2 | 0.647 |
No | 18 (22.0) | 10.3 | |
Weight loss≥5% | |||
Yes | 26 (31.7) | 9.3 | 0.734 |
No | 56 (68.3) | 10.2 | |
Number of BMs | |||
1 | 21 (25.6) | 12.6 | 0.034* |
2–3 | 24 (29.3) | 10.3 | |
> 3 | 37 (45.1) | 6.8 | |
Interval from diagnosis of SCLC to BMs (month) | |||
≤ 10 | 40 (48.7) | 9.2 | 0.204 |
> 10 | 42 (51.3) | 10.3 | |
Maximum diameter of the largest tumor (cm) | |||
≤ 2.0 | 44 (53.6) | 12.6 | 0.002* |
> 2.0 | 38 (46.3) | 9.4 | |
Symptomatic BMs | |||
Yes | 27 (32.9) | 9.0 | 0.039* |
No | 55 (67.1) | 10.3 | |
Treatment regimen before BMs | |||
Concurrent CRT | 28 (33.7) | 9.8 | 0.880 |
Sequential CRT | 54 (66.3) | 9.6 | |
Extracranial disease status | |||
Progressive | 15 (18.3) | 5.1 | 0.016* |
Control | 67 (81.7) | 10.3 | |
Brain RT regimen | |||
WBRT | 49 (59.8) | 8.5 | 0.004* |
WBRT plus boost | 33 (40.2) | 13.4 |